Hopes that the immunosuppressive drug tocilizumab would help improves outcomes for acute GVHD in patients undergoing allogeneic SCT have been dashed by an Australian study. While the interleukin-6 inhibitor showed a trend towards benefit when used in volunteer-unrelated-donors, it not significantly reduce the incidence of grade II-IV acute GVHD, a phase 3 randomised controlled trial ...
Australian trial reveals tocilizumab effect in acute GVHD
By Michael Woodhead
2 Feb 2021